With the growing global health concern regarding obesity, Novo’s WEGOVY (semaglutide) has emerged as a leading solution in the weight loss treatment market. WEGOVY is a GLP-1 receptor agonist used alongside a low-calorie diet and increased physical activity. This obesity medication is administered as a weekly subcutaneous injection, offering convenience and consistency in obesity management.
In June 2021, the FDA approved WEGOVY injections for long-term weight management in adults. This obesity drug’s approval marked a significant milestone in the field of obesity treatment. WEGOVY has been a dominant force in the lucrative obesity market, which is poised to reach ...
